Evidence map›Paper›PMID 33054135›Full record

ArticleHaematologica2020

Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.

Davine Hofste op Bruinink, Stefania Oliva, Lucie Rihova, Alexander Schmitz, Milena Gilestro, Jeroen Te Marvelde, Romana Kralova, Helle Høholt, Annemiek Broijl, Hans Erik Johnsen and 5 more

Abstract readLetter
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Davine Hofste op BruininkDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . d.hofsteopbruinink@erasmusmc.nl.
Stefania OlivaMyeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
Lucie RihovaDepartment of Hematology, University Hospital Brno, Brno, Czech Republic.
Alexander SchmitzDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Milena GilestroMyeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
Jeroen Te MarveldeLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
Romana KralovaDepartment of Hematology, University Hospital Brno, Brno, Czech Republic.
Helle HøholtDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Annemiek BroijlDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Hans Erik JohnsenDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
Roman HajekDepartment of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic.
Mario BoccadoroMyeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Paola OmedèMyeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
Vincent H J Van der VeldenLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands . v.h.j.vandervelden@erasmusmc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaFeasibility StudiesFlow CytometryHumansNeoplasm, ResidualReference Standards

Identifiers

PMID33054135
PMCPMC8094105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.